PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of orphjrdisBioMed CentralBiomed Central Web Sitesearchsubmit a manuscriptregisterthis articleOrphanet Journal of Rare DiseasesJournal Front Page
 
Orphanet J Rare Dis. 2010; 5: 35.
Published online 2010 December 3. doi:  10.1186/1750-1172-5-35
PMCID: PMC3014877

Case report of intrafamilial variability in autosomal recessive centronuclear myopathy associated to a novel BIN1 stop mutation

Abstract

Centronuclear myopathies (CNM) describe a group of rare muscle diseases typically presenting an abnormal positioning of nuclei in muscle fibers. To date, three genes are known to be associated to a classical CNM phenotype. The X-linked neonatal form (XLCNM) is due to mutations in MTM1 and involves a severe and generalized muscle weakness at birth. The autosomal dominant form results from DNM2 mutations and has been described with early childhood and adult onset (ADCNM). Autosomal recessive centronuclear myopathy (ARCNM) is less characterized and has recently been associated to mutations in BIN1, encoding amphiphysin 2. Here we present the first clinical description of intrafamilal variability in two first-degree cousins with a novel BIN1 stop mutation. In addition to skeletal muscle defects, both patients have mild mental retardation and the more severely affected male also displays abnormal ventilation and cardiac arrhythmia, thus expanding the phenotypic spectrum of BIN1-related CNM to non skeletal muscle defects. We provide an up-to-date review of all previous cases with ARCNM and BIN1 mutations.

Background

Centronuclear myopathies (CNM) are a group of congenital disorders characterized by hypotonia and skeletal muscle biopsies typically showing small rounded fibers with central nuclei [1-4]. Abnormal nuclear positioning is seen in several myopathies, but clinical, genetic and pathological factors clearly distinguish these myopathies from CNM. Three CNM classes have been described: the severe neonatal X-linked form, also called myotubular myopathy (XLCNM, OMIM 310400), the autosomal recessive form with childhood onset (ARCNM, OMIM 255200), and the autosomal dominant form with adult onset (ADCNM, OMIM 160150). Myotubularin (MTM1) is mutated in XLCNM [5] and belongs to a large family of ubiquitously expressed phosphoinositide phosphatases implicated in intracellular vesicle trafficking [6-8]. The large GTPase dynamin 2 (DNM2), mutated in ADCNM, is a mechanochemical enzyme and a key factor in membrane trafficking and endocytosis [9-11]. Amphiphysin 2 (BIN1) is mutated in ARCNM and possesses an N-terminal BAR domain able to sense and bend membranes and a SH3 domain mediating protein-protein interactions [12,13]. A muscle-specific isoform is implicated in T-tubule biogenesis and contains a polybasic residue sequence binding to phosphoinositides [14]. Only 4 unrelated individuals with BIN1 mutations have been molecularly and clinically characterized to date [12,15] and this report is the first description of intrafamilal variability in two patients from a consanguineous family. Clinical analysis of respiratory and cardiac involvement diagnosed for the more severely affected male patient expand the phenotypic spectrum in autosomal recessive centronuclear myopathy. It is furthermore the first time that patients with a BIN1 mutation are analyzed by whole-body MRI and the results contrast previous findings on DNM2-related CNM.

Clinical report and results

Patient 1 is a 13 year old girl belonging to a consanguineous family from Turkey without ancestral history of neuromuscular disorders (Figure 1A-B). There were no complications during pregnancy, antenatal signs for muscle disorders as polyhydramnios and reduced fetal movements were not noted. Hypotonia was diagnosed at birth and motor development was delayed: head control was achieved at 6 months, walking at 18 months and running at 36 months. Muscle weakness was predominantly proximal, accompanied by mild facial weakness, ptosis and ophtalmoplegia/paresis. Tendinous reflexes were absent and she has no contractures. Although she has mild mental retardation (IQ 60), speech development was normal and she integrated the regular educational system. Echocardiography, electrocardiography and electroneuromyography were normal, and there were no indications of myotonia or neuromuscular junction abnormalities. Serum creatine kinase was mildly elevated [380 IU/L (70-150); normal range 60 - 320 IU/L]. She is currently walking independently but she has difficulty climbing stairs and running. Pulmonary function tests are normal. Patient 1 has one non-affected sister and none of the parents displays clinical features of a muscle disorder.

Figure 1
Clinical, histological and MRI features in the patients. (A) Pedigree of the consanguineous family of both ARCNM patients. Segregation of the mutation (c.1717C > T in NM_139343) in the tested individuals is depicted as black dots; both patients ...

Patient 2, a 14 year old boy, is the first-degree cousin of patient 1 and belongs to a second consanguineous family loop (Figure 1A-B). The course of the disease was rather similar to patient 1 with normal pregnancy, hypotonia at birth, delayed motor milestones and normal speech development despite a mild mental retardation (IQ 60). Head control was achieved at 6 months, walking at 18 months and running at 36 months. Likewise, patient 2 presents a predominantly proximal muscle weakness, absent tendinous reflexes, facial weakness, ptosis and opthalmoplegia/paresis. However, his phenotype is more severe as he is not able to walk independently since the age of 10 years and is wheelchair-bound. Furthermore, the degree of ophtalmoplegia/paresis and ptosis is more prominent than in patient 1. In addition, electrocardiography and HOLTER examination revealed premature ventricular complexes while echocardiography was normal. Serum creatine kinase was 450 IU/L (70-150) and electromyography revealed myopathic changes in all muscle groups. He needs non-invasive respiratory support for four hours per day. Patient 2 has healthy parents and 3 non-affected siblings.

Whole body MRI of both patients revealed similar results with increased signals on T2 and T1 weighted images in thigh muscles, upper and lower extremities which are consistent with fatty infiltrations. Detailed axial imaging of the femoral and crural regions of patient 1 revealed prominent fatty involvement of soleus, tibialis anterior, peroneal and extensor muscles, but sparing of the gastrocnemius (Figure (Figure1C).1C). All thigh muscle groups were affected without selective pattern. Imaging of upper limb demonstrated relative sparing of triceps, subscapularis and flexor muscle groups (Figure (Figure1C).1C). No abnormalities of brain, heart or other organs were noted.

Diagnosis of CNM for both patients was suggested on muscle biopsies showing numerous centrally located and partially clustered nuclei, variable fiber size, type 1 fiber predominance, extensive myofibrillar disorganization (Figure (Figure1F)1F) and fibrosis (Figure (Figure1D).1D). Dystrophin expression was normal (Figure (Figure1E).1E). BIN1 sequencing revealed a homozygous nonsense mutation in exon 20 in both patients (c.1717C > T; p.Gln573stop). Both patients have healthy parents heterozygous for this mutation.

Discussion

By direct sequencing of the 20 BIN1 exons and the adjacent splice-relevant regions we identified the novel homozygous nonsense BIN1 mutation p.Gln573stop in two first-degree cousins from a consanguineous family. Both patients present predominantly proximal muscle weakness and classical features of CNM with a general progressive hypotonia involving facial weakness and ptosis. Ophtalmoplegia/paresis, as seen in both patients, is not a common sign of ARCNM (Table (Table1),1), while it is consistently reported for the X-linked form. However, Ophtalmoplegia/paresis often evolves over time and might not have been diagnosed in all BIN1 patients due to their young age. Whole body MRI showed fatty infiltrations of different muscle groups with selective muscle involvement in the lower leg, and a general muscle involvement in the thigh. This contrasts MRI findings in DNM2-related centronuclear myopathies where prominent fatty atrophy was predominantly documented in the lower leg muscles, but only in specific thigh muscles: increased signals were reported for adductor longus, semimembranosus, rectus femoris, biceps femoris, and vastus intermedius muscles, while the adductor magnus, gracilis, sartorius, semitendinosus, vastus lateralis, and vastus medialis muscles were only minimally affected [16].

Table 1
Clinical comparison of all patients with known BIN1 mutations

This is consistent with the observation that ARCNM patients with BIN1 mutations predominantly display a proximal muscle weakness (Table (Table1),1), whereas ADCNM patients with DNM2 mutations rather present involvement of the distal muscles [17]. Characterization of additional ARCNM and ADCNM patients is required to confirm that MRI could be used as a differential marker to direct genetic diagnosis.

To our knowledge, this is the second documented ARCNM family with more than one molecularly characterized member. Nicot et al. reported a family with three affected members, two of which died within the first year of life, precluding a long term comparison of clinical signs [[12], Table Table1].1]. In the present study we observed a clear intra-familiar variability, which might be linked to gender or modifier genes differing between individuals. Patient 2 does not walk independently, has a more pronounced ophtalmoplegia/paresis and ptosis, and electroneuromyography revealed myopathic changes not detected in patient 1. Patient 2 has also been diagnosed for additional respiratory system and cardiac involvements. Abnormal ventilation has been documented for two other autosomal recessive cases [[15,18], Table Table1]1] and a further patient died at birth due to respiratory failure [[12], Table Table1].1]. Cardiac arrhythmia was stated for patient 2, while ECG examinations did not reveal abnormalities for patient 1. As cardiac abnormalities have been reported for another ARCNM patient who died from myocarditis shortly after birth [[12], Table Table1],1], we suggest careful cardiac function examinations and long term follow-up of patients with BIN1 mutations.

A mild mental retardation, as seen in both patients, has recently been described in another ARCNM patient [[15], Table Table1].1]. Mental impairment was not noticed in the other BIN1-patients and is rarely present in other CNM forms. However, decreased synaptic vesicle recycling in the murine brain was described in amphiphysin 1 knockout mice, suggesting a possible pathological mechanism affecting cognitive abilities [19]. We though cannot exclude that the mental retardation might not be correlated to the BIN1 mutation, especially in a consanguineous family.

BIN1 was initially identified as a c-Myc interacting pro-apoptotic tumor suppressor [20]; BIN1 expression is reduced in several cancers and mice deficient for BIN1 develop more aggressive tumors [21,22]. However, no tumors were reported in the small set of ARCNM patients with BIN1 mutations.

The novel p.Gln573stop mutation described in this study is in direct spatial proximity to the previously identified p.Lys575stop mutation, which results in the expression of a truncated protein with decreased dynamin 2 binding [12]. At the time of publication, the p.Lys575stop patient was 17 years old, able to walk short distances, had normal cognitive development and no cardiac involvement [[12,18], Table Table1],1], contrasting the present study. Table Table11 gives an overview of the clinical manifestations of all currently published BIN1 patients. Disease onset at birth was stated for all patients except for ADR71 and AEY47 (p.Asp151Asn and pArg154Gln, respectively), harboring adjacent missense mutations in the BAR-domain and presenting a generally milder etiopathology. The identification of more BIN1 mutations and respective detailed clinical descriptions might help to establish an unambiguous genotype/phenotype correlation and to clarify if the most 3' BIN1 exon represents a hot spot prone to mutations.

In conclusion, this study expands the phenotypic spectrum of BIN1-related centronuclear myopathy and is the first clinical description of intrafamilial variability in a consanguineous CNM family.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

JB carried out the molecular genetics studies. UY, SHK and ED carried out the clinical investigation. RO carried out the histologic studies. HC carried out MRI. JB and JL wrote the manuscript. JL conceived and coordinated the study. All authors have read and approved the final manuscript

Consent

Written informed consent was obtained from the patient's parents for publication of these case reports and accompanying images.

Acknowledgements

The authors thank the patients and families for their participation. This study was supported by the Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS), University of Strasbourg, Collège de France, the Association Française contre les Myopathies (AFM), Fondation Recherche Médicale, Agence Nationale de la Recherche and E-rare program. Johann Böhm was supported by the Deutsche Forschungsgemeinschaft (DFG).

References

  • Jeannet PY, Bassez G, Eymard B. et al. Clinical and histologic findings in autosomal centronuclear myopathy. Neurology. 2004;62:1484–1490. [PubMed]
  • Jungbluth H, Wallgren-Pettersson C, Laporte J. Centronuclear (myotubular) myopathy. Orphanet J Rare Dis. 2008;3(1):26. doi: 10.1186/1750-1172-3-26. [PMC free article] [PubMed] [Cross Ref]
  • Wallgren-Pettersson C, Clarke A, Samson F, Fardeau M, Dubowitz V, Moser H, Grimm T, Barohn RJ, Barth PG. The myotubular myopathies: differential diagnosis of the X linked recessive, autosomal dominant, and autosomal recessive forms and present state of DNA studies. J Med Genet. 1995;32:673–9. doi: 10.1136/jmg.32.9.673. [PMC free article] [PubMed] [Cross Ref]
  • Pierson CR, Tomczak K, Agrawal P, Moghadaszadeh B, Beggs AH. X-linked myotubular and centronuclear myopathies. J Neuropathol Exp Neurol. 2005;64:555–64. [PubMed]
  • Laporte J, Hu LJ, Kretz C. et al. A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast. Nat Genet. 1996;13:175–182. doi: 10.1038/ng0696-175. [PubMed] [Cross Ref]
  • Laporte J, Bedez F, Bolino A. et al. Cooperation and specificity of catalytically active and inactive myotubularin phosphoinositides phosphatases. Hum Mol Genet. 2003;12:285–92. doi: 10.1093/hmg/ddg273. [PubMed] [Cross Ref]
  • Laporte J, Liaubet L, Blondeau F, Tronchere H, Mandel JL, Payrastre B. Functional redundancy in the myotubularin family. Biochem Biophys Res Commun. 2002;291:305–312. doi: 10.1006/bbrc.2002.6445. [PubMed] [Cross Ref]
  • Cao C, Laporte J, Backer JM, Wandinger-Ness A, Stein M-P. Myotubularin lipid phosphatase binds the hVPS15/hVPS34 lipid kinase complex on endosomes. Traffic. 2007;8:1052–1067. doi: 10.1111/j.1600-0854.2007.00586.x. [PubMed] [Cross Ref]
  • Bitoun M, Maugenre S, Jeannet PY. et al. Mutations in dynamin 2 cause dominant centronuclear myopathy. Nat Genet. 2005;37:1207–1209. doi: 10.1038/ng1657. [PubMed] [Cross Ref]
  • Praefcke GJ, McMahon HT. The dynamin superfamily: universal membrane tubulation and fission molecules? Nat Rev Mol Cell Biol. 2004;5:133–47. doi: 10.1038/nrm1313. [PubMed] [Cross Ref]
  • Bitoun M, Bevilacqua JA, Prudhon B, Maugenre S, Taratuto AL, Monges S, Lubieniecki F, Cances C, Uro-Coste E, Mayer M, Fardeau M, Romero NB, Guicheney P. Dynamin 2 mutations cause sporadic centronuclear myopathy with neonatal onset. Ann Neurol. 2007;62:666–70. doi: 10.1002/ana.21235. [PubMed] [Cross Ref]
  • Nicot AS, Toussaint A, Tosch V. et al. Mutations in amphiphysin 2 (BIN1) disrupt interaction with dynamin 2 and cause autosomal recessive centronuclear myopathy. Nat Genet. 2007;39:1134–1139. doi: 10.1038/ng2086. [PubMed] [Cross Ref]
  • Itoh T, De Camilli P. BAR, F-BAR (EFC) and ENTH/ANTH domains in the regulation of membrane-cytosol interfaces and membrane curvature. Biochim Biophys Acta. 2006;1761:897–912. [PubMed]
  • Lee E, Marcucci M, Daniell L. et al. Amphiphysin 2 (Bin1) and T-tubule biogenesis in muscle. Science. 2002;297:1193–6. doi: 10.1126/science.1071362. [PubMed] [Cross Ref]
  • Claeys KG, Maisonobe T, Böhm J. et al. Phenotype of a patient with recessive centronuclear myopathy and a novel BIN1 mutation. Neurology. 2010;74:519–521. doi: 10.1212/WNL.0b013e3181cef7f9. [PubMed] [Cross Ref]
  • Schessl J, Medne L, Hu Y. et al. MRI in DNM2-related centronuclear myopathy: evidence for highly selective muscle involvement. Neuromuscul Disord. 2007;17(1):28–32. doi: 10.1016/j.nmd.2006.09.013. [PubMed] [Cross Ref]
  • Fischer D, Herasse M, Bitoun M, Barragán-Campos HM, Chiras J, Laforêt P, Fardeau M, Eymard B, Guicheney P, Romero NB. Characterization of the muscle involvement in dynamin 2-related centronuclear myopathy. Brain. 2006;129:1463–9. doi: 10.1093/brain/awl071. [PubMed] [Cross Ref]
  • Mejaddam AY, Nennesmo I, Sejersen T. Severe phenotype of a patient with autosomal recessive centronuclear myopathy due to a BIN1 mutation. Acta Myol. 2009;XXVIII:91–93. [PMC free article] [PubMed]
  • Di Paolo G, Sankaranarayanan S, Wenk MR. et al. Decreased synaptic vesicle recycling efficiency and cognitive deficits in amphiphysin 1 knockout mice. Neuron. 2002;33:789–804. doi: 10.1016/S0896-6273(02)00601-3. [PubMed] [Cross Ref]
  • Sakamuro D, Elliott KJ, Wechsler-Reya R, Prendergast GC. BIN1 is a novel MYC-interacting protein with features of a tumour suppressor. Nat Genet. 1996;14:69–77. doi: 10.1038/ng0996-69. [PubMed] [Cross Ref]
  • Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Targeted deletion of the suppressor gene bin1/amphiphysin2 accentuates the neoplastic character of transformed mouse fibroblasts. Cancer Biol Ther. 2004;3:1236–1242. doi: 10.4161/cbt.3.12.1232. [PubMed] [Cross Ref]
  • Ge K, Minhas F, Duhadaway J, Mao NC, Wilson D, Buccafusca R, Sakamuro D, Nelson P, Malkowicz SB, Tomaszewski J, Prendergast GC. Loss of heterozygosity and tumor suppressor activity of Bin1 in prostate carcinoma. Int J Cancer. 2000;86:155–61. doi: 10.1002/(SICI)1097-0215(20000415)86:2<155::AID-IJC2>3.0.CO;2-M. [PubMed] [Cross Ref]

Articles from Orphanet Journal of Rare Diseases are provided here courtesy of BioMed Central